中国药科大学生命科学与技术学院研究生导师介绍：徐寒梅

• 2025考研英语全程班 早鸟3班
• 26考研全科上岸规划营「择校▪规划▪备考」
• 中国药科大学2025考研专业课复习资料「真题▪笔记▪讲义▪题库」

徐寒梅，女，中国药科大学生命科学与技术学院教授，博士生导师，海洋药学教研室主任。自2002年于南京大学国家医药生物技术重点实验室进行博士后研究期间，开始抗肿瘤蛋白质及多肽的研究。2004年底到中国药科大学工作，继续从事抗肿瘤多肽的研究，设计合成了抗肿瘤多肽安替安吉肽,AP25，EDSM等具有自主知识产权的多肽，其中安替安吉肽于2013年9月获得一类新药临床批件。近五年在国内外发表学术文章50余篇，SCI20余篇；主编及参编论著各一部，主编教材《海洋制药学》一部；申请发明专利共25项(其中国际专利5项)。近五年以来，先后主持了：国家自然科学基金，国家“863”高科技发展计划，国家“十一五”、“十二五”“重大新药创制”科技重大专项，江苏省校企合作前瞻性研究等项目，近五年带领课题组（包括南京大学、武汉大学、广州药学院、医药企业）获得国家资助3800余万元。因与企业合作抗肿瘤多肽研究的表现获得内蒙古自治区“杰出创新引进人才”奖，“草原英才”；近五年先后获得江苏省“青蓝工程”优秀骨干教师，中青年学术带头人，南京市领军人才等奖励和称号；因为产学研合作的表现被内蒙古自治区政府聘为科技特派员;被教育部“蓝火工程”聘为泰州市科技特派员。

联系方式：1037714870@qq.com

办公电话：86-025-86185437

近五年以第一作者或通讯作者发表的SCI论文文章

1. Shen Hong, Han Haibing, Hu Jialiang, Zhang Xiaojuan, Wang Jingjing, Wang Wenjing, Nie Caihui, Xu Hanmei*. PEGylated HM-3 presents anti-rheumatic bioactivity by inhibiting angiogenesis and inflammation. Journal of Materials Chemistry B, 2014, 2:800-813.
2. Jialiang Hu, Ming Yan, ChunyanPu, Jingjing Wang, Philippe E. Van den steen, GhislainOpdenakker, HanmeiXu*. Chemically synthesized matrix metalloproteinase- and angiogenesis-inhibiting peptides as anticancer agents. Anti-cancer Reagents ME. 2014 Mar;14(3):483-94.
3. Dongqing Yuan , Hong Shen , Songtao Yuan , Xiaoyi Liu, Xin Xia, Ping Xie , Weiguang Li , Jialiang Hu , Qinghuai Liu , Hanmei Xu*. Pharmacokinetics of HM-3 after intravitreal administration in mice. Current Eye Research. 2014, Feb 21,online.
4. Li Yongbing, Xu Hanmei*, Hu Jialiang, Zhang Fengguo, Liu Zhendong, Zhang Chi, Yang Yongjing, Pu Chunyan, Quantitative Analysis and Pharmacokinetics Study of Integrin Antagonist AP25 in Rat Plasma, Protein Pept Lett. 2012 Sep 4. [Epub ahead of print]
5. Chunyan Pu，Hanmei Xu*, Jialiang Hu, Zheng Heng, Xiaofeng Huang, Zhang Chi; Yongjing Yang, Yongbing Li, RGD position has effect on anti-angiogenic activity of RGD modified endostation derived synthetic polypeptides. Anti-cancer drugs. 2012, 12: 788-802
6. Li Pan1, Jialiang Hu1, Wenjing Wang1, Xiaojuan Zhang1, Jin Wei1, Zhendong Liu1, Yihua Zhang2* and Hanmei Xu1*. Molecular Mechanisms of (R,R) ZX-5 on NO Synthesis and Its Anti-Angiogenic Effect. International Journal of Molecular Sciences. 2012, 13, 2717-2726.
7. Liu Zhendong, Li Weiguang, Xu Hanmei*, Huang Xiaofeng, Pan Li, Ren Yinling, Yang Yongjing, Li Yongbing, Pu Chunyan, Zhang Chi. In vivo pharmacokinetics, immunogenicity and mechanism of PEGylated anti-tumor polypeptide. Current Pharmaceutical Design. 2012,18(12):1655-1662.
8.Guoqiu Wu, Xuepeng Deng，Pengpeng Wu, Zilong Shen, Hanmei Xu*, Subacute toxicity of antimicrobial peptide S-thanatin in ICR mice. Peptides 2012, 36 ( 1 ): 109-13.
9. Hanmei Xu*, Li Pan, Yinling Ren , et al.An RGD-Modified Angiogenesis Inhibitor HM-3 Dose: Dual Function during Cancer Treatment. Bioconjugate Chem., 2011, 22 (7): 1386–1393.
10. Zhendong Liu, Yinling Ren, Li Pan and Han-Mei Xu*, In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG). Int. J. Mol. Sci. 2011, 12(4), 2650-2663.
11. Guoqiu Wu,Xuepeng Deng , Hanmei Xu*, et al. Application of immobilized thrombin for production of S-thanatin expressed in Escherichia coli. Appl Microbiol Biotechnol. 2011, 92(1):85-93.
12. Han-Mei Xu, Jin Wei, Zilong Shen1*, et al. The Mechanism of (R, R) ZX-5 Promoting Choroidal Blood Flow and Increasing NO Release, Int. J. Mol. Sci. 2010, 11(9), 3323-3333.
13. Ning-Hua Tan, Yu-Mei Zhang, Han-Mei Xu*, et al. A New Abietane Diterpene from Glyptostrobus pensilis, Fitoterapia,2010,81(8):1202-4.
14.Kang Zhou, Beili Zhu, Han-Mei Xu*, et al.Studies of polyethylene glycol modification of HM-3 polypeptides，Conference paper of 2010 Nanjing International Symposium on Pharmacogenomics and the Regulation of Drug Metabolism Enzymes and Genes, Journal of Nanjing University, 2010, Vol.46, 127-132
15. Beili Zhu, Han-Mei Xu*, Liming zhao, et al. Site-specific modification of antiangiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa , Journal of Biochemistry, 2010, 148(3): 341-347
16. Runting Yin, Tao Xi and Han-Mei Xu*, et al. Effect of RGD-4C Position is More Important Than Disulfide Bonds on Antiangiogenic Activity of RGD-4C Modified Endostatin Derived Synthetic Polypeptide, bioconjugate chemistry, 2010, 6(1): 1142-1147
17. Zhou K, Zheng XQ, Xu HM* , et al. Studies of Poly(ethylene glycol) Modification of HM-3 Polypeptides, bioconjugate chemistry, 2010, 20(5): 932-936.
18. Han-Mei Xu*, Runting Yin, Xianghua Chen, et al. An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo，bioconjugate chemistry, 2008, 19(10): 1980-1986.
19. Siraj Sami, Han-Mei Xu*, Zilong Shen , et al. Valproic Acid Inhibits the Growth of Cervical Cancer both In vitro and In vivo, ， 144(3): 357-362.Journal of Biochemistry,2008